Results 211 to 220 of about 276,902 (250)

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Real-World Effectiveness Following Benralizumab Use in Patients with Severe Eosinophilic Asthma in Romania: A Retrospective Cohort Study (BREEZE). [PDF]

J Clin Med
Toma CL, Teodorescu G, Mihălţan FD, Frent S, Ali S, Trenchea M, Constantin AA.   +6 more
europepmc   +1 more source

Butyrate Modulates CXCR4 Expression and IL‐5‐Induced Inflammatory Responses in Human Eosinophils

Allergy, EarlyView.
Emiko Matsuyama, Jun Miyata, Yusuke Kawashima, Ryo Konno, Yoshinori Hasegawa, Masahito Mizobe, Yuri Fukasawa, Ryuta Onozato, Yo Otsu, Keeya Sunata, Hisashi Sasaki, Katsunori Masaki, Hiroki Kabata, Makoto Arita, Koichi Fukunaga   +14 more
wiley   +1 more source

The fight of innate immunity and abnormal cannabinoids against Candida infection

British Journal of Pharmacology, EarlyView.
Candida species represent the most clinically significant fungal pathogens in humans, with invasive candidiasis carrying a mortality of 30%–40% in critically ill patients despite modern antifungal therapy. The innate immune system – through the coordinated and specific activities of neutrophils, macrophages, NK cells, mast cells and eosinophils ...
Prince Ofori, Ilan Zaffran, Francesca Levi Schaffer   +2 more
wiley   +1 more source

Determinants of Clinical Remission in Dupilumab-Treated Severe Eosinophilic Asthma: A Real-World Retrospective Study. [PDF]

Biomedicines
Bonato M, Favero E, Savoia F, Drigo M, Rizzato S, Orzes E, Senna G, Romagnoli M.   +7 more
europepmc   +1 more source

Established Tissue Eosinophilia is Not Synonymous With Ongoing Local Type 2 Cytokine Activity

Allergy, EarlyView.
Franziska U. Nordström, Malin Lindstedt, Lennart Greiff, Jonas S. Erjefält   +3 more
wiley   +1 more source

Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP. [PDF]

J Asthma Allergy
Garcia-Rivero JL, Abascal-Bolado B, Aranda Sobrino N, Ghadban Garrido C.   +3 more
europepmc   +1 more source

Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE study. [PDF]

ERJ Open Res
Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Caminati M.   +22 more
europepmc   +1 more source

Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2. [PDF]

Clin Exp Allergy
Penz E, Rothe T, Dupont L, Tran TN, Menzies-Gow A, Shavit A, Cohen D, Plate T, Kayaniyil S, Herreman A, Schuoler C, Emmanuel B, Lommatzsch M.   +12 more
europepmc   +1 more source